Raymond Osarogiagbon, MBBS, FACP(@ROsarogiagbon) 's Twitter Profileg
Raymond Osarogiagbon, MBBS, FACP

@ROsarogiagbon

Director of the Multidisciplinary Thoracic Oncology Program and the Thoracic Oncology Research (ThOR) Group at the Baptist Cancer Center, in Memphis, TN

ID:1370422968845762562

calendar_today12-03-2021 17:14:39

74 Tweets

354 Followers

70 Following

Raymond Osarogiagbon, MBBS, FACP(@ROsarogiagbon) 's Twitter Profile Photo

Being in the center of the lung cancer mortality belt of America, we are striving to narrow this gap by 25% in the next 10 years & eliminate the stigma of lung cancer in the Mid-South. Find out more about the Mid-South Miracle on the Right Care podcast. player.captivate.fm/episode/6cf246…

account_circle
Jason Gerali(@jgerali) 's Twitter Profile Photo

Study led by Raymond Osarogiagbon, MBBS, FACP at Baptist Health Cancer Center highlights the need for incidental detection of lung nodules. USPSTF guidelines are a great start but only a start. Qure.ai
ascopubs.org/doi/10.1200/JC…

account_circle
Stephen V Liu, MD(@StephenVLiu) 's Twitter Profile Photo

Dr. Raymond Osarogiagbon, MBBS, FACP shows the significant state variation in low-dose CT screening for lung cancer. The rates are the lowest in areas where the need is the greatest (outlier is Kentucky where rates are very high).

#PLCClive22 Dr. @ROsarogiagbon shows the significant state variation in low-dose CT screening for lung cancer. The rates are the lowest in areas where the need is the greatest (outlier is Kentucky where rates are very high). #HealthCareDisparities #LCSM
account_circle
Medicine Matters oncology(@MM_Oncology) 's Twitter Profile Photo

News: US research finds low rates of use of some standard therapies for resectable, early non-small-cell lung cancer. Read more about the study by Kenneth Kehl of Dana-Farber, Dr. Shakun Malik Suresh S. Ramalingam, MD, FASCO Raymond Osarogiagbon, MBBS, FACP & colleagues in JAMA Oncology bit.ly/3txsRAA

account_circle
NCI Supportive Care(@NCISymptomMgmt) 's Twitter Profile Photo

help broaden access to cancer care, offering people options that did not exist 50 years ago. “That's exciting, but none of it has any value,” said Dr. Raymond Osarogiagbon, MBBS, FACP, “if it doesn’t benefit all populations.” buff.ly/3GVN4UX

#ClinicalTrials help broaden access to cancer care, offering people options that did not exist 50 years ago. “That's exciting, but none of it has any value,” said Dr. @ROsarogiagbon, “if it doesn’t benefit all populations.” buff.ly/3GVN4UX #NothingWillStopUs
account_circle
Raymond Osarogiagbon, MBBS, FACP(@ROsarogiagbon) 's Twitter Profile Photo

Be sure to check out Baptist Cancer Center's LCAM event at Crosstown Concourse tomorrow! Our organization is committed to raising awareness of lung cancer and reducing lung cancer rates not only in the Mid-South but nationally. RSVP at the link below:
baptistcancer.center/lung-cancer-aw…

account_circle
CURE Today(@cure_today) 's Twitter Profile Photo

Looking deeper into mortality rates highlights the importance of eliminating disparities in lung cancer and expanding screening eligibility for at-risk populations. Raymond Osarogiagbon, MBBS, FACP Vanderbilt School of Medicine

curetoday.com/view/facing-di…

account_circle
Raymond Osarogiagbon, MBBS, FACP(@ROsarogiagbon) 's Twitter Profile Photo

As an , I believe it's essential for non-small cell patients to receive biomarker testing to inform treatment. This KNOWvember, spread the word on the importance of patients receiving testing using .

As an #NOMPartner, I believe it's essential for non-small cell #lungcancer patients to receive biomarker testing to inform treatment. This KNOWvember, spread the word on the importance of #NSCLC patients receiving testing using #KnowYourBiomarker. #NoOneMissed #LCAM
account_circle
Nancy Keating(@NancyKeatingMD) 's Twitter Profile Photo

Good news: Modest savings and no evidence for skimping or harm
Disappointing news: Huge investments in care did not lead to notable improvements in quality, patient experiences, or outcomes.
Nice editorial by Raymond Osarogiagbon, MBBS, FACP Samyukta Mullangi Deborah Schrag 9/n

account_circle
Raymond Osarogiagbon, MBBS, FACP(@ROsarogiagbon) 's Twitter Profile Photo

As an , I'm proud to support LUNGevity Foundation in recognizing KNOWvember as part of . It's vital that all non-small cell patients receive comprehensive biomarker testing to inform treatment. *Insert Link*

As an #NOMPartner, I'm proud to support @LUNGevity in recognizing KNOWvember as part of #LungCancerAwarenessMonth. It's vital that all non-small cell #lungcancer patients receive comprehensive biomarker testing to inform treatment. *Insert Link* #KnowYourBiomarker #NoOneMissed
account_circle